Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wizz Air posts jump in Q2 profit and revenues

(Sharecast News) - Wizz Air posted a jump in second quarter revenues and profits, even as it "refocused" the business and pared its leverage. The Eastern Europe-focused low-cost carrier's total revenues grew by 13.4% over the three months ending on 30 June to reach roughly €1.43bn, whilst operating profit in EBITDA terms improved by 9.3% to €300.2m.

Looking ahead, chief executive officer, Jozsef Varadi, "our management team has demonstrated a high degree of adaptability in recent years when faced by severe challenges, and this year will likely continue to call on that strength as we refocus our business.

"We see this encompassing some significant changes to our operations but with active execution and a strong balance sheet to support this, I am excited by the long-term prospects for the company."

The carrier's load factor however was unchanged 91.1%, although the size of its fleet size increased by 8.3% to 236 aircraft.

Approximately seventeen million passengers were carried by Wizz Air during the period, for a 10.6% improvement on the year earlier quarter.

Net debt was trimmed by 5.1% to reach roughly €4.71bn.

Total cash at period end stood at €1.97bn, a 13.2% improvement.

As of 1142 BST, shares of Wizz Air were trading down by 2.40% at 1,057.0p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.